{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Albumin, serum-low (hypoalbuminemia)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Allergy/Immunology-Other"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Bilirubin (hyperbilirubinemia)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Edema: limb"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Extremity-lower (gait/walking)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Fatigue (asthenia, lethargy, malaise)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hemoglobin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Inf (clin/microbio) w/Gr 3-4 neuts - Lung"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Leukocytes (total WBC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Lymphopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Muscle weakness, not d/t neuropathy - Extrem-lower"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Muscle weakness, not d/t neuropathy - body/general"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Neuropathy: motor"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Neuropathy: sensory"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Neutrophils/granulocytes (ANC/AGC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Platelets"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"To evaluate the qualitative and quantitative toxicities associated with this regimen.","groups":[{"description":"Induction (per 21-day cycle): Bortezomib - 1.0 mg/m2 (Days 1, 4, 8, and 11). Dexamethasone - 20 mg/d PO (Days 1, 2, 4, 5, 8, 9, 11, and 12). Thalidomide 100 mg (Days 1-21).\n\nMaintenance (per 28-day cycle): thalidomide 100mg (Days 1-28). Dexamethasone 40 mg Days 1-4.","id":"OG000","title":"Bortezomib + Thal/Dex"}],"paramType":"NUMBER","populationDescription":"All participants receiving at least one dose of induction therapy","reportingStatus":"POSTED","timeFrame":"From date of protocol therapy start to date of protocol therapy end, i.e., up to about 3.5 years","title":"Toxicity Evaluation","type":"SECONDARY","unitOfMeasure":"Participants"}